// App-Quantinova.ai

: Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Researchers

Presenter

  • Max S. Topp

Principal Investigators

  • Monica Tani

  • Michael Dickinson

  • Nilanjan Ghosh

  • Armando Santoro

  • Antonio Pinto

  • Francesc Bosch

  • Christopher P. Fox

  • Armando Lopez-Guillermo

  • Claudia Carlucci

  • Chun Wu

  • Kathryn Humphrey

  • Pauline Baumlin

  • Martin Barrett

  • Naseer Qayum

  • Franck Morschhauser

Medical Centers

  • Ospedale Santa Maria delle Croci, Ravenna, Italy

  • Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Australia

  • UniversitäTsklinikum WüRzburg, Würzburg, Germany

  • Humanitas University and IRCCS Humanitas Research Hospital, Humanitas Cancer Center, Milan, Italy

  • Hospital Clinic de Barcelona, Barcelona, Spain

  • Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom

  • Istituto Nazionale Tumori, Fondazione 'G. Pascale', IRCCS, Naples, Italy

  • Levine Cancer Institute/Atrium Health, Charlotte, NC

  • Hospital Universitari Vall D'Hebron, Barcelona, Spain

  • Hôpital Claude Huriez Univ. Lille, CHU Lille, ULR - GRITA - Groupe de Recherche sur les formes Injectables et les Technologies Associées and Centre Hospitalier Régional Universitaire de Lille, Lille, France

Locations

  • Italy

  • China

  • United States

  • United Kingdom

  • Australia

  • Spain

  • Switzerland

  • Germany

  • France

Companies

  • F. Hoffmann-La Roche

  • Feng Chi Biotech Cor

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Autoimmune (AI)

Disease

  • Diffuse large B-cell lymphoma

  • Cytokine release syndrome

  • B cell lymphomas

  • Lymphomas

Biomarkers

  • Twist-related protein 1

Drug/Treatment

  • Rituximab

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved